You just read:

Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohn's Disease

News provided by

Takeda Pharmaceutical Company Limited

21 Aug, 2013, 22:40 BST